Versions Compared


  • This line was added.
  • This line was removed.
  • Formatting was changed.
Comment: edits from pharmacy 5/23 call


FHIR Core version(s):

R4, since C-CDA on FHIR IG STU 1.1 is based on R4

Maintenance Plan:


This IG provides pharmacist- and pharmacy-specific guidance and requirements for the use of C-CDA on FHIR IG (STU 1.1) Consultation Note for a Pharmacist Consultation Note.  This addresses sections that are required or recommended for a Pharmacist Consultation Note, which may differ from C-CDA on FHIR IG and US Core.  Identifies required or recommended code sets/value sets for pharmacy use cases.


The Pharmacist Consultation Note IG provides requirements and recommendations for using C-CDA on FHIR IG (STU 1.1) Consultation Note in pharmacy use cases.  The audience for this IG are system vendors, especially pharmacy system vendors, where the system/application supports pharmacists with medication review and other consulting services.  Examples include:  a pharmacist's medication regimen review for LTPAC patients; reporting of evaluations performed in a pharmacist-run clinic; and a pharmacist responding to a provider-requested review and recommendations for a patient's medications relative to their conditions, allergies, etc.

This IG also provides guidance on the use of C-CDA R2.1 for Pharmacist Consultation Notes.  At the present time, C-CDA documents are widely used and previous guidance described C-CDA implementation for consulting pharmacists.  This IG updates that prior guidance and includes material to facilitate the Pharmacist Consultation Note transition from C-CDA to FHIR (C-CDA on FHIR IG).

Involved parties:


Pharmacy HIT Collaborative


dependent on C-CDA on FHIR IG 1.1.0 - (FHIR R4) STU Release 1.1 and its dependencies